123 related articles for article (PubMed ID: 16397271)
1. Interplay between two hormone-independent activation domains in the androgen receptor.
Callewaert L; Van Tilborgh N; Claessens F
Cancer Res; 2006 Jan; 66(1):543-53. PubMed ID: 16397271
[TBL] [Abstract][Full Text] [Related]
2. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J
Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028
[TBL] [Abstract][Full Text] [Related]
4. Identification of the functional domains of ANT-1, a novel coactivator of the androgen receptor.
Fan S; Goto K; Chen G; Morinaga H; Nomura M; Okabe T; Nawata H; Yanase T
Biochem Biophys Res Commun; 2006 Mar; 341(1):192-201. PubMed ID: 16414017
[TBL] [Abstract][Full Text] [Related]
5. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor.
Haelens A; Tanner T; Denayer S; Callewaert L; Claessens F
Cancer Res; 2007 May; 67(9):4514-23. PubMed ID: 17483368
[TBL] [Abstract][Full Text] [Related]
6. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
9. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
10. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
12. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
13. Ala 586 Asp mutation in androgen receptor disrupts transactivation function without affecting androgen binding.
Rajender S; Gupta NJ; Chakrabarty B; Singh L; Thangaraj K
Fertil Steril; 2009 Mar; 91(3):933.e23-8. PubMed ID: 19062009
[TBL] [Abstract][Full Text] [Related]
14. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
15. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
Kraus S; Gioeli D; Vomastek T; Gordon V; Weber MJ
Cancer Res; 2006 Nov; 66(22):11047-54. PubMed ID: 17108144
[TBL] [Abstract][Full Text] [Related]
16. A central domain of cyclin D1 mediates nuclear receptor corepressor activity.
Petre-Draviam CE; Williams EB; Burd CJ; Gladden A; Moghadam H; Meller J; Diehl JA; Knudsen KE
Oncogene; 2005 Jan; 24(3):431-44. PubMed ID: 15558026
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor: unlocking the secrets of its unique transactivation domain.
Shen HC; Coetzee GA
Vitam Horm; 2005; 71():301-19. PubMed ID: 16112272
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia increases androgen receptor activity in prostate cancer cells.
Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
[TBL] [Abstract][Full Text] [Related]
19. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response.
Verrijdt G; Tanner T; Moehren U; Callewaert L; Haelens A; Claessens F
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1089-94. PubMed ID: 17073757
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]